Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MALTOMA
MCID: LYM129
MIFTS: 70

Lymphoma, Mucosa-Associated Lymphoid Type (MALTOMA)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

MalaCards integrated aliases for Lymphoma, Mucosa-Associated Lymphoid Type:

Name: Lymphoma, Mucosa-Associated Lymphoid Type 58 76 39
Malt Lymphoma 58 39 12 60 76 56 15 17
Mucosa-Associated Lymphoid Tissue Lymphoma 12 60 74
Gastric Lymphoma, Primary 58 76 56
Lymphoma, Malt, Somatic 58 76 13
Extranodal Marginal Zone B-Cell Lymphoma 60 74
Marginal Zone B-Cell Lymphoma 76 74
Maltoma 60 76
Mucosa-Associated Lymphatic Tissue Lymphoma 60
Familial Primary Gastric Lymphoma 74
Lymphoma, B-Cell, Marginal Zone 45
Lymphoma, Gastric, Primary 41
Primary Gastric Lymphoma 76
Gastric Lymphoma 74

Characteristics:

Orphanet epidemiological data:

60
malt lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (United States),1-9/100000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Gastrointestinal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare haematological diseases


Sources

Summaries for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
UniProtKB/Swiss-Prot : 76 Lymphoma, mucosa-associated lymphoid type: A subtype of non-Hodgkin lymphoma, originating in mucosa-associated lymphoid tissue. MALT lymphomas occur most commonly in the gastro- intestinal tract but have been described in a variety of extranodal sites including the ocular adnexa, salivary gland, thyroid, lung, thymus, and breast. Histologically, they are characterized by an infiltrate of small to medium-sized lymphocytes with abundant cytoplasm and irregularly shaped nuclei. Scattered transformed blasts (large cells) also are present. Non-malignant reactive follicles are observed frequently. A pivotal feature is the presence of lymphoepithelial lesions, with invasion and partial destruction of mucosal glands and crypts by aggregates of tumor cells.

MalaCards based summary : Lymphoma, Mucosa-Associated Lymphoid Type, also known as malt lymphoma, is related to nodal marginal zone b-cell lymphoma and follicular lymphoma. An important gene associated with Lymphoma, Mucosa-Associated Lymphoid Type is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Amoxicillin and Clarithromycin have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are hyperhidrosis and nausea and vomiting

Disease Ontology : 12 A marginal zone B-cell lymphoma that has material basis in mucosal tissue involved in antibody production.

OMIM : 58 The concept of mucosa-associated lymphoid tissue (MALT) lymphomas was introduced by Isaacson and Wright (1983). MALT lymphomas are now recognized as a distinct subtype of non-Hodgkin lymphoma (605027). B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphomas) are the most common form of lymphoma arising in extranodal sites, in most cases arising in the gastric mucosa (Isaacson and Spencer, 1995). (137245)

Sources

Related Diseases for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Diseases related to Lymphoma, Mucosa-Associated Lymphoid Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 227)
# Related Disease Score Top Affiliating Genes
1 nodal marginal zone b-cell lymphoma 34.8 BCL6 MALT1
2 follicular lymphoma 33.0 BCL10 BCL6 CCND1
3 lymphoma 32.2 BCL10 BCL6 CCND1 CXCR5 MALT1
4 diffuse large b-cell lymphoma 31.0 BCL10 BCL6 CARD11 CD5 FOXP1 MALT1
5 marginal zone b-cell lymphoma 30.9 BCL10 BCL6 BIRC3 CCND1 CD5 FOXP1
6 b-cell lymphomas 30.8 BCL10 BCL6 BIRC3 CARD11 CCND1 CD40
7 composite lymphoma 30.8 BCL6 CD5
8 follicular lymphoma 1 30.6 BCL10 BCL6 IGH
9 central nervous system lymphoma 30.6 BCL6 FOXP1 MALT1
10 mantle cell lymphoma 30.5 BCL6 CCND1 CD40 CD5 IGH MALT1
11 primary cutaneous marginal zone b-cell lymphoma 30.4 BCL10 MALT1
12 lung lymphoma 30.4 BCL6 BIRC3 CD5 MALT1
13 breast lymphoma 30.4 BCL6 CD5
14 chromosomal triplication 30.3 BCL6 MALT1
15 prostate lymphoma 30.3 BIRC3 CD5 MALT1
16 splenic marginal zone lymphoma 30.2 BCL6 BIRC3 CD5 MALT1
17 peripheral t-cell lymphoma 30.0 BCL6 CD5 CXCL13 CXCR3
18 leukemia, chronic lymphocytic 29.8 BCL10 BCL6 CCND1 CD40 CD5 CXCR3
19 lymphoma, non-hodgkin, familial 29.4 BCL10 BCL6 BIRC3 CCND1 CD40 CD5
20 nodal marginal zone lymphoma 11.5
21 adenocarcinoma 10.5
22 helicobacter pylori infection 10.4
23 gastritis 10.4
24 testicular lymphoma 10.4 BCL6 FOXP1
25 orofaciodigital syndrome viii 10.4 BCL10 BIRC3 MALT1
26 intravascular large b-cell lymphoma 10.4 BCL6 CD5
27 tracheal lymphoma 10.4
28 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.4 BCL6 CXCR5
29 primary mediastinal large b-cell lymphoma 10.4 BCL6 FOXP1
30 sjogren syndrome 10.3
31 gastric adenocarcinoma 10.3
32 gastric cancer 10.3
33 leukemia, acute lymphoblastic 3 10.3 CXCR5 FOXP1 IGH
34 adenoma 10.3
35 t-cell/histiocyte rich large b cell lymphoma 10.3 BCL6 IGH
36 leukocyte disease 10.3 BCL6 CCND1 CD5 MALT1
37 thyroiditis 10.3
38 neurosyphilis 10.2 CXCL13 CXCR5
39 autoimmune disease 10.2
40 langerhans cell histiocytosis 10.2
41 hepatitis b 10.2
42 hairy cell leukemia 10.2
43 dacryoadenitis 10.2
44 igg4-related ophthalmic disease 10.2
45 chlamydia 10.2
46 macroglobulinemia 10.2
47 gastrointestinal system disease 10.1 CCND1 MADCAM1 S100A8
48 systemic lupus erythematosus 10.1
49 lymphoma, hodgkin, classic 10.1
50 hepatitis 10.1

Graphical network of the top 20 diseases related to Lymphoma, Mucosa-Associated Lymphoid Type:



Diseases related to Lymphoma, Mucosa-Associated Lymphoid Type
Sources

Symptoms & Phenotypes for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Human phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

60 33 (show all 19)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 60 33 hallmark (90%) Very frequent (99-80%) HP:0000975
2 nausea and vomiting 60 33 hallmark (90%) Very frequent (99-80%) HP:0002017
3 fever 60 33 hallmark (90%) Very frequent (99-80%) HP:0001945
4 fatigue 60 33 hallmark (90%) Very frequent (99-80%) HP:0012378
5 anemia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001903
6 weight loss 60 33 hallmark (90%) Very frequent (99-80%) HP:0001824
7 pulmonary infiltrates 60 33 hallmark (90%) Very frequent (99-80%) HP:0002113
8 b-cell lymphoma 60 33 hallmark (90%) Very frequent (99-80%) HP:0012191
9 constipation 60 33 frequent (33%) Frequent (79-30%) HP:0002019
10 recurrent respiratory infections 60 33 occasional (7.5%) Occasional (29-5%) HP:0002205
11 visual impairment 60 33 occasional (7.5%) Occasional (29-5%) HP:0000505
12 abdominal pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0002027
13 mediastinal lymphadenopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0100721
14 abnormality of the thyroid gland 60 33 occasional (7.5%) Occasional (29-5%) HP:0000820
15 posterior uveitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0012123
16 abnormal nasolacrimal system morphology 33 occasional (7.5%) HP:0000614
17 lymphadenopathy 60 Occasional (29-5%)
18 abnormality of the nasolacrimal system 60 Occasional (29-5%)
19 gastric lymphoma 33 HP:0045038

Clinical features from OMIM:

137245

GenomeRNAi Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.74 BCL10 BIRC2 BIRC3 CARD11 DUSP5 MALT1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.74 BCL10 BIRC2 BIRC3 CARD11 DUSP5 MALT1

MGI Mouse Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1
2 cellular MP:0005384 10 BCL10 BCL6 BIRC2 BIRC3 CCND1 CXCL13
3 immune system MP:0005387 9.83 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1
4 normal MP:0002873 9.28 BCL6 BIRC2 BIRC3 CCND1 CCR6 CD40
Sources

Drugs & Therapeutics for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Drugs for Lymphoma, Mucosa-Associated Lymphoid Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 513)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
2
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81103-11-9 84029
3
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
4
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
6
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
7
Esomeprazole Approved, Investigational Phase 4,Phase 2 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
8
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 52-24-4 5453
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antimalarials Phase 4,Phase 2,Phase 1
25 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
27
rituximab Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
28
Vidarabine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 24356-66-9 21704 32326
29
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
30
Pixantrone Approved, Investigational Phase 3 144510-96-3
31
Iron Approved, Experimental Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 23925 27284
32
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
33
Clavulanate Approved, Vet_approved Phase 3,Not Applicable 58001-44-8 5280980
34 Orange Approved Phase 3
35
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
36
Ofloxacin Approved Phase 3 82419-36-1 4583
37
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
38
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
39
Idarubicin Approved Phase 3 58957-92-9 42890
40
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 460612 4053
41
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
42
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
44
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
45
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
46
Prednisone Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 53-03-2 5865
47
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
48
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
49
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
50
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462

Interventional clinical trials:

(show top 50) (show all 713)
# Name Status NCT ID Phase Drugs
1 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Recruiting NCT02553083 Phase 4 Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
2 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
4 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
7 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
10 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
11 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
12 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
13 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
14 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
15 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
16 Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma Active, not recruiting NCT00210353 Phase 3 chlorambucil (drug);rituximab+chlorambucil;rituximab
17 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) Active, not recruiting NCT01938001 Phase 3 Rituximab;Lenalidomide;Placebo
18 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
19 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. Recruiting NCT01996865 Phase 3 Lenalidomide;Rituximab
20 Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma Completed NCT00310167 Phase 3
21 Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma Completed NCT01701232 Phase 3
22 A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Recruiting NCT03078855 Phase 3
23 A Phase â…¢ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Completed NCT02302170 Phase 3
24 A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) Withdrawn NCT02576275 Phase 3 Duvelisib;Placebo;Rituximab;Bendamustine
25 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
26 Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed NCT00255190 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR
27 Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Recruiting NCT02793583 Phase 2, Phase 3 TGR-1202 + Ublituximab;TGR-1202;TGR-1202 + Ublituximab + Bendamustine
28 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3 Bendamustine;Standard chemotherapy CHOP + Ritiximab
29 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
30 Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas Active, not recruiting NCT00877214 Phase 3 Rituximab;Rituximab / observation
31 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
32 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
33 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
34 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
35 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
36 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
37 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
38 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
39 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
40 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
41 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
42 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
43 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
44 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
45 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
46 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
47 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
48 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
49 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
50 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3

Search NIH Clinical Center for Lymphoma, Mucosa-Associated Lymphoid Type

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Mucosa-Associated Lymphoid Type cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lymphoma, Mucosa-Associated Lymphoid Type:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Lymphoma, Mucosa-Associated Lymphoid Type:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: lymphoma, b-cell, marginal zone

Sources

Genetic Tests for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
Sources

Anatomical Context for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

MalaCards organs/tissues related to Lymphoma, Mucosa-Associated Lymphoid Type:

42
B Cells, Bone, Bone Marrow, Breast, T Cells, Thyroid, Lung
Sources

Publications for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Articles related to Lymphoma, Mucosa-Associated Lymphoid Type:

(show top 50) (show all 882)
# Title Authors Year
1
Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy. ( 30847823 )
2019
2
Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the lacrimal drainage system in two pediatric patients. ( 30862184 )
2019
3
Endobronchial mucosa-associated lymphoid tissue (MALT) lymphoma. ( 30895318 )
2019
4
Frontline Antibiotic Therapy for Early Stage Helicobacter Pylori Negative Gastric MALT Lymphoma. ( 30785215 )
2019
5
Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa- Associated Lymphoid Tissue (MALT) Lymphoma. ( 30769175 )
2019
6
Gastric MALT lymphoma presented with primary perforation in an adolescent: a case report. ( 30782170 )
2019
7
Cutaneous granulomatous lesions in a patient with mucosa-associated lymphoid tissue (MALT) lymphoma. ( 30697684 )
2019
8
18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report. ( 30702589 )
2019
9
Extranodal Marginal Zone B Cell (MALT) Lymphoma of the Esophagus. ( 30618000 )
2019
10
Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy. ( 29582109 )
2018
11
Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary SjAPgren syndrome (pSS). ( 29424433 )
2018
12
Epstein-Barr virus-positive mucocutaneous ulcer colliding with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (malt lymphoma) that developed in the palatine tonsils of an immunocompetent patient after gastric lymphoma relapse. ( 30588472 )
2018
13
Simultaneous Occurrence of Colonic Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma (MALToma) and Lung Cancer. ( 30631608 )
2018
14
HRCT in primary pulmonary lymphoma: can CT imaging phenotypes differentiate histological subtypes between mucosa-associated lymphoid tissue (MALT) lymphoma and non-MALT lymphoma? ( 30622775 )
2018
15
Clinical presentation and treatment outcomes of primary ocular adnexal MALT lymphoma in Thailand. ( 30588468 )
2018
16
Gastric MALT lymphoma and Helicobacter pylori. ( 30424932 )
2018
17
MALT lymphoma: epidemiology, clinical diagnosis and treatment. ( 30364585 )
2018
18
Mucosal-associated Lymphoid Tissue (MALT) Lymphoma in Association With Pediatric Primary Sjogren Syndrome: 2 Cases and Review. ( 30371536 )
2018
19
Prognostic role of baseline 18 F-FDG PET/CT parameters in MALT lymphoma. ( 30299563 )
2018
20
Sequential H. pylori eradication and radiation therapy with reduced dose compared to standard dose for gastric MALT lymphoma stages IE & II1E: a prospective randomized trial. ( 30327875 )
2018
21
Treatment Choice for Primary Rectal MALT lymphoma. ( 30215790 )
2018
22
Colorectal MALT lymphoma: a rare clinical entity. ( 30103227 )
2018
23
Gastric malt lymphoma mickmicking a submucosal tumor with complete response after chemotherapy. ( 30032924 )
2018
24
DWI-MRI vs CT in gastric MALT lymphoma-preliminary results in 19 patients. ( 30040435 )
2018
25
Rectal MALT lymphoma regression and anti-Helicobacter pylori therapy. ( 29961825 )
2018
26
Synchronous MALT lymphoma of the colon and stomach and regression after eradication of Strongyloides stercoralis and Helicobacter pylori. ( 29970607 )
2018
27
Clarithromycin as a "repurposing drug" against MALT lymphoma. ( 28771670 )
2018
28
Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma. ( 29102522 )
2018
29
A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy. ( 29411260 )
2018
30
Mucosa-associated lymphoid-tissue (MALT) lymphoma of the rectum. ( 29474645 )
2018
31
Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma. ( 29563121 )
2018
32
Gastric MALT Lymphoma with Increased Plasma Cell Differentiation Showing Unique Endoscopic Features. ( 29666720 )
2018
33
Neuroendocrine Neoplasia in Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) of the Lung: A Case Report and Immunohistochemistry Analysis of Eight Pulmonary MALT Lymphomas. ( 29673288 )
2018
34
Evaluation of the diagnostic value of immunoglobulin clonal gene rearrangements in patients with parotid gland MALT lymphoma using BIOMED-2 protocol. ( 29699947 )
2018
35
MALT Lymphoma, Stress Ulcer and Cholinergic Nerves from the Viewpoint of Bilateral and Unilateral Truncal Vagotomy and Substance P. ( 29766790 )
2018
36
Rituximab monotherapy become an optimal treatment for primary pulmonary malt lymphoma. ( 29892543 )
2018
37
Multiple keratotic papules and plaques on the trunk in Cowden's disease with MALT lymphoma. ( 28391632 )
2018
38
Nodular pulmonary amyloidosis with primary pulmonary MALT lymphoma masquerading as metastatic lung disease. ( 28808514 )
2017
39
Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma. ( 28331132 )
2017
40
Primary pulmonary MALT lymphoma presenting as non-resolving pneumonia. ( 28871587 )
2017
41
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). ( 28833354 )
2017
42
MALT lymphoma arising on a background of reactive pulmonary lymphoid hyperplasia in a patient with Systemic Lupus Erythematosus. ( 28945277 )
2017
43
A primary esophageal MALT lymphoma patient with<i>Helicobacter pylori</i>infection achieved complete remission after<i>H. pylori</i>eradication without anti-lymphoma treatment. ( 28053856 )
2017
44
A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. ( 28695630 )
2017
45
Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Colon: A Case Report and a Literature Review. ( 28469125 )
2017
46
Radiotherapy for mucosa-associated lymphoid tissue (MALT) lymphoma of the rectum: a case report. ( 28815477 )
2017
47
A MALT lymphoma prognostic index. ( 28720586 )
2017
48
MALT1 sequencing analyses in marginal zone B-cell lymphomas reveal mutations in the translocated MALT1 allele in an IGH-MALT1-positive MALT lymphoma. ( 28278699 )
2017
49
Treatment outcome and risk analysis for cataract after radiotherapy of localized ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma. ( 29037024 )
2017
50
A case of API2-MALT1-positive gastric MALT lymphoma with concomitant diffuse large B-cell lymphoma. ( 28626260 )
2017
Sources

Variations for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Cosmic variations for Lymphoma, Mucosa-Associated Lymphoid Type:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM35925 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1004T>G p.L335* 6:137878449-137878449 0
2 COSM303672 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.559C>T p.Q187* 6:137875760-137875760 0
3 COSM303675 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1507C>T p.Q503* 6:137878952-137878952 0
4 COSM303674 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1282G>T p.E428* 6:137878727-137878727 0
5 COSM303671 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.733A>T p.R245* 6:137876094-137876094 0
6 COSM303679 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.581T>C p.I194T 6:137875782-137875782 0
7 COSM303677 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1367G>T p.G456V 6:137878812-137878812 0
8 COSM303694 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1485T>A p.C495* 6:137878930-137878930 0
9 COSM36072 NOTCH2 haematopoietic and lymphoid tissue,extranodal,lymphoid neoplasm,MALT lymphoma c.4912C>T p.H1638Y 1:119922726-119922726 0
10 COSM85940 MYD88 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.794T>C p.L265P 3:38141150-38141150 0

Copy number variations for Lymphoma, Mucosa-Associated Lymphoid Type from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 119732 18 16100000 76117153 Gain MALT1 Mucosa-associated lymphoid tissue lymphomas
2 206010 6 135101251 139048099 Loss TNFAIP3 Mucosa-associated lymphoid tissue lymphomas
Sources

Expression for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
Search GEO for disease gene expression data for Lymphoma, Mucosa-Associated Lymphoid Type.
Sources

Pathways for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Pathways related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 13.84 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1
2
Akt Signaling 65
Show member pathways
 13.28 CCND1 CCR6 CD40 CXCL13 CXCR3 CXCR5
3
Cytokine Signaling in Immune system 67
Show member pathways
 13.23 BCL6 BIRC2 BIRC3 CCND1 CD40 DUSP5
4
CCR5 Pathway in Macrophages 65
Show member pathways
 12.75 CCND1 CCR6 CXCL13 CXCR3 CXCR5
5
NF-KappaB Family Pathway 65
Show member pathways
 12.54 BCL10 CARD11 CD40 MALT1 TRAF2
6
Immune response NFAT in immune response 23
Show member pathways
 12.47 BCL10 CARD11 CD40 IGH MALT1
7
Allograft rejection 1 38
Show member pathways
 12.35 BCL10 CARD11 CCND1 CD40 CXCL13 CXCR5
8
NF-kappaB Signaling 4
12.31 BCL10 BCL6 CARD11 CXCR5 MALT1 TRAF2
9
ICos-ICosL Pathway in T-Helper Cell 65
Show member pathways
 12.24 BCL10 CARD11 CD40 MALT1
10
B cell receptor signaling pathway (KEGG) 38
Show member pathways
 12.22 BCL10 BCL6 CARD11 MALT1
11
Apoptosis and Autophagy 4
12.03 BCL10 BIRC2 BIRC3 MALT1 TRAF2
12
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 66
Show member pathways
 11.86 CCR6 CXCL13 CXCR3 CXCR5
13
TNF signaling pathway 38
11.83 BIRC2 BIRC3 TRAF2
14
TCR signaling in naive CD4+ T cells 1
Show member pathways
 11.81 BCL10 CARD11 MALT1
15
Small cell lung cancer 38
11.73 BIRC2 BIRC3 CCND1 TRAF2
16
LT-BetaR Pathway 65
Show member pathways
 11.68 BIRC2 CXCL13 TRAF2
17
Innate Lymphoid Cell Differentiation Pathways 66
11.65 CCR6 CXCR3 CXCR5
18
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 23
Show member pathways
 11.57 BIRC2 BIRC3 CD40 TRAF2
19
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.51 BIRC2 BIRC3 CCND1
20
B Cell Development Pathways 66
11.28 BCL6 CD40 CD5 CXCR5
21
NF-kappa B signaling pathway 38
11.15 BCL10 BIRC2 BIRC3 CARD11 CD40 MALT1
22
Canonical NF-kappaB pathway 1
11.01 BCL10 BIRC2 MALT1
23
CD40/CD40L signaling 1
10.93 BIRC2 BIRC3 CD40 TRAF2
Sources

GO Terms for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Cellular components related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.8 BCL10 BIRC2 BIRC3 HSPD1 MALT1 TRAF2
2 external side of plasma membrane GO:0009897 9.65 CCR6 CD40 CD5 CXCR3 CXCR5
3 membrane raft GO:0045121 9.35 BCL10 BIRC2 BIRC3 CARD11 TRAF2
4 CD40 receptor complex GO:0035631 9.33 BIRC2 CD40 TRAF2
5 CBM complex GO:0032449 8.8 BCL10 CARD11 MALT1

Biological processes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.99 BIRC2 BIRC3 CXCL13 CXCR3
2 regulation of immune response GO:0050776 9.96 BCL6 CARD11 CD40 MADCAM1
3 T cell receptor signaling pathway GO:0050852 9.88 BCL10 CARD11 MALT1
4 Fc-epsilon receptor signaling pathway GO:0038095 9.88 BCL10 CARD11 MALT1
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.88 CCR6 CXCL13 CXCR3 CXCR5
6 response to ethanol GO:0045471 9.87 BIRC2 CCND1 S100A8
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.86 HSPD1 S100A8 TRAF2
8 calcium-mediated signaling GO:0019722 9.85 CCR6 CXCR3 CXCR5
9 positive regulation of protein ubiquitination GO:0031398 9.83 BCL10 BIRC3 MALT1
10 chemotaxis GO:0006935 9.83 CCR6 CXCL13 CXCR3 CXCR5 S100A8
11 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.81 BCL10 CARD11 MALT1
12 cell chemotaxis GO:0060326 9.81 CCR6 CXCL13 CXCR3 CXCR5
13 protein heterooligomerization GO:0051291 9.8 BCL10 BIRC2 BIRC3 TRAF2
14 chemokine-mediated signaling pathway GO:0070098 9.78 CCR6 CXCL13 CXCR3 CXCR5
15 tumor necrosis factor-mediated signaling pathway GO:0033209 9.76 BIRC2 BIRC3 CD40 TRAF2
16 positive regulation of B cell proliferation GO:0030890 9.75 BCL6 CARD11 CD40
17 regulation of inflammatory response GO:0050727 9.72 BCL6 BIRC2 BIRC3 FOXP1 S100A8
18 B cell proliferation GO:0042100 9.71 CARD11 CD40 HSPD1
19 B cell activation GO:0042113 9.71 CD40 CXCR5 HSPD1 MALT1
20 NIK/NF-kappaB signaling GO:0038061 9.7 BIRC2 BIRC3
21 activation of NF-kappaB-inducing kinase activity GO:0007250 9.7 MALT1 TRAF2
22 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.7 BIRC2 BIRC3 TRAF2
23 positive regulation of interleukin-2 production GO:0032743 9.69 MALT1 TRAF2
24 regulation of innate immune response GO:0045088 9.69 BIRC2 BIRC3
25 negative regulation of necroptotic process GO:0060546 9.68 BIRC2 BIRC3
26 response to molecule of bacterial origin GO:0002237 9.67 BCL10 MALT1
27 leukocyte migration involved in inflammatory response GO:0002523 9.67 CCR6 S100A8
28 positive regulation of T cell activation GO:0050870 9.67 BCL10 CARD11 HSPD1 MALT1
29 negative regulation of B cell apoptotic process GO:0002903 9.66 BCL6 FOXP1
30 positive regulation of T cell cytokine production GO:0002726 9.66 MALT1 TRAF2
31 chronic inflammatory response GO:0002544 9.65 CXCL13 S100A8
32 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.65 BCL10 BIRC2 BIRC3 CARD11 TRAF2
33 germinal center formation GO:0002467 9.64 BCL6 CXCL13
34 inhibition of cysteine-type endopeptidase activity involved in apoptotic process GO:1990001 9.63 BIRC2 BIRC3
35 regulation of necroptotic process GO:0060544 9.63 BIRC2 BIRC3
36 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.63 BCL10 CARD11 CD40 MALT1 S100A8 TRAF2
37 response to fungus GO:0009620 9.62 BCL10 MALT1
38 regulation of T cell receptor signaling pathway GO:0050856 9.61 BCL10 MALT1
39 regulation of toll-like receptor signaling pathway GO:0034121 9.61 BIRC2 BIRC3
40 regulation of immunoglobulin secretion GO:0051023 9.59 CD40 TRAF2
41 regulation of cysteine-type endopeptidase activity GO:2000116 9.57 BIRC2 BIRC3
42 regulation of nucleotide-binding oligomerization domain containing signaling pathway GO:0070424 9.56 BIRC2 BIRC3
43 regulation of RIG-I signaling pathway GO:0039535 9.55 BIRC2 BIRC3
44 regulation of apoptotic process GO:0042981 9.5 BCL10 BCL6 BIRC2 BIRC3 CARD11 MALT1
45 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.17 BCL10 BIRC2 BIRC3 CARD11 CD40 MALT1
46 negative regulation of apoptotic process GO:0043066 10.09 BCL6 BIRC2 BIRC3 HSPD1 MALT1
47 apoptotic process GO:0006915 10.09 BCL10 BIRC2 BIRC3 CXCR3 S100A8 TRAF2
48 immune response GO:0006955 10.07 CCR6 CXCL13 CXCR3 CXCR5 MADCAM1
49 inflammatory response GO:0006954 10 BCL6 CD40 CXCL13 CXCR3 S100A8

Molecular functions related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 ubiquitin-protein transferase activity GO:0004842 9.8 BIRC2 BIRC3 MALT1 TRAF2
2 ubiquitin protein ligase binding GO:0031625 9.73 BCL10 CD40 HSPD1 TRAF2
3 enzyme binding GO:0019899 9.65 BCL10 CCND1 CD40 HSPD1 TRAF2
4 protein self-association GO:0043621 9.5 BCL10 FOXP1 MALT1
5 protease binding GO:0002020 9.48 BCL10 MALT1
6 CARD domain binding GO:0050700 9.46 BCL10 CARD11
7 C-X-C chemokine receptor activity GO:0016494 9.4 CXCR3 CXCR5
8 kinase activator activity GO:0019209 9.37 BCL10 MALT1
9 chemokine binding GO:0019956 9.33 CCR6 CXCR3 CXCR5
10 C-C chemokine binding GO:0019957 9.13 CCR6 CXCR3 CXCR5
11 C-C chemokine receptor activity GO:0016493 8.8 CCR6 CXCR3 CXCR5
12 protein binding GO:0005515 10.41 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1
Sources

Sources for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....